-
So, my first question is on the line of since we are talking about CMO, CDMO. So, a lot of R&D effort would be going on in this direction. But at the same time, molecules come and go. Every project would not be successful, but there would be a lot of learning coming out of it.
Read in transcript -
My second question would be around, with all these learnings and the efforts that are going into R&D, how we are trying to build a system. Let's say, right now, we talk a lot about launching products, one product after another. But from going through the block of, let's say, growth of 2-3 years, how we are trying to build a system which thinks in terms of block of 5 years, 7 years, 10 years.
Read in transcript -
Just one point like as last participant also mentioned that since we are moving into direction with interaction with maybe our partners would be of much larger size, innovators and the other stuff is compliance piece becomes pretty critical. Any lapse there would cost us a bit. So, hopefully this is one of the incidents which happened , and it will not be a recurring thing. Thanks for all the answers.
Read in transcript
Analyst questions
Rishabh Tripathi
Firm not listed in source transcripts
1Call
1Company
SUPRIYA
All company callsSupriya Lifescience Limited
Supriya Lifescience Limited
14 Aug 2026